Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 6/20 | 0.77 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.70 |
| ▸ | PPARG | P37231 | 3/20 | 0.69 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.69 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.69 |
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.65 |
| ▸ | MME | P08473 | 1/20 | 0.63 |
| ▸ | ACE | P12821 | 1/20 | 0.63 |
| ▸ | CPA1 | P15085 | 1/20 | 0.63 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.63 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.62 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.62 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.61 |
| ▸ | CDC25B | P30305 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27871431 | 1.00 | GPR132 (0.77) | GPR132PTPN1PPARGITGB3ITGA2B | |
| SCHEMBL1123232 | 0.97 | GPR132 (0.77) | GPR132PTPN1PPARGITGB3ITGA2B | |
| SCHEMBL1123299 | 0.97 | GPR132 (0.77) | GPR132PTPN1PPARGITGB3ITGA2B | |
| SCHEMBL1123033 | 0.97 | GPR132 (0.77) | GPR132PTPN1PPARGITGB3ITGA2B | |
| SCHEMBL27658914 | 0.97 | GPR132 (0.77) | GPR132PTPN1PPARGITGB3ITGA2B | |
| SCHEMBL1122757 | 0.96 | GPR132 (0.78) | GPR132PTPN1PPARGITGB3ITGA2B | |
| SCHEMBL5927205 | 0.94 | GPR132 (0.72) | GPR132PTPN1PPARGITGB3ITGA2B | |
| SCHEMBL1123243 | 0.94 | GPR132 (0.72) | GPR132PTPN1PPARGITGB3ITGA2B | |
| SCHEMBL1122833 | 0.94 | GPR132 (0.72) | GPR132PTPN1PPARGITGB3ITGA2B | |
| SCHEMBL1123309 | 0.93 | GPR132 (0.71) | GPR132PTPN1PPARGITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161415-B1 | N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6593327-B2 | N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates | AXYS PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| US-20030119788-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-06-26 | — | — | US | disclosed |
| US-6476026-B1 | Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020086996-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | US | disclosed |
| EP-1161415-A2 | N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000055126-A2 | N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| US-4742067-A | Acylalkylaminocarbonyl substituted amino and imino acid compounds | E. R. SQUIBB & SONS, INC. (US) | 1988-05-03 | — | — | US | disclosed |
| US-4736066-A | Intermediate for substituted peptide compounds | E. R. SQUIBB & SONS, INC. (US) | 1988-04-05 | — | — | US | disclosed |
| US-4621092-A | HYPOTENSIVE, ANALGESIC | E. R. SQUIBB & SONS, INC. (US) | 1986-11-04 | — | — | US | disclosed |
| US-4604402-A | HYPOTENSIVE AGNETS | E. R. SQUIBB & SONS, INC. (US) | 1986-08-05 | — | — | US | disclosed |
| EP-0159156-A1 | Hydroxy substituted ureido amino and imino acids | E.R. Squibb & Sons, Inc. (US) | 1985-10-23 | — | — | EP | disclosed |
| US-4535176-A | HYPOTENSIVE AGENTS, ANALGESICS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1985-08-13 | — | — | US | disclosed |
| US-4470973-A | HYPOTENSIVE AGENTS, ANALGESICS | E. R. SQUIBB & SONS, INC. (US) | 1984-09-11 | — | — | US | disclosed |
| EP-0103496-A1 | Acylalkylaminocarbonyl substituted amino and imino acid compounds | E.R. Squibb & Sons, Inc. (US) | 1984-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086996-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | GPR132 4535/4885PTPN1 1580/4885PPARG 4602/4885 |
| US-20030119788-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | GPR132 4535/4885PTPN1 1580/4885PPARG 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.